eISSN 2508-3589
pISSN 2508-1926

Table. 6.

Table. 6.

Change following IVB according to OCT-based type of DME

Variable Diffuse type (n = 13) CME type (n = 8) SRF type (n = 9) p-value
CRT
Pre-IVB 388.3 ± 85.6 473.8 ± 290.1 461.8 ± 121.0 0.294*
Post-IVB 352.9 ± 70.6 341.8 ± 68.7 285.6 ± 84.0 0.103*
p-value 0.017 0.093 0.017
Geometric
Pre-IVB UACR 118.2 (34.8-401.5) 117.4 (35.7-386.1) 90.9 (22.0-375.6) 0.938*
Post-IVB UACR 144.6 (55.8-374.9) 104.2 (26.1-415.6) 102.0 (26.0-400.8) 0.784*
p-value 0.279 0.484 0.374
Categorical change of UACR‡ 0.685§
Improved change 1 (8) 1 (13) 2 (22)
No change in category 10 (77) 7 (87) 6 (67)
Aggravated change 2 (15) 0 (0) 1 (11)

Values are presented as mean ± standard deviation, mean (95% confidence interval) or number (%).

IVB = intravitreal bevacizumab injection; OCT = optical coherence tomography; DME = diabetic macular edema; CME = cystoid macular edema; SRF = subretinal fluid; CRT = central retinal thickness; UACR = urinary albumin-to-creatinine ratio.

Kruskal-Wallis test;

Wilcoxon signed rank test comparing pre-IVB and post-IVB data; ‡improved changes were from A3 to A1 or A2 and from A2 to A1, while aggravated changes were from A1 to A2 or A3 and from A2 to A3;

chi-square test.

J Retin 2019;4:69-76 https://doi.org/10.21561/jor.2019.4.2.69
© 2019 J Retin